Vaccines, Blood & Biologics
Record of Telephone Conversation - Cervarix, Sept. 1, 2009
System Info - 104046 SHONE, DEANNA 02-Sep-2009 11:05:54 SHONEDE
RECORD OF TELEPHONE CONVERSATION
Submission Type: Original Application Submission ID: 125259/0 Office: OVRR
Product:
Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant
Applicant:
GlaxoSmithKline Biologicals
Telecon Date/Time: 01-SEP-2009 05:57 PM Initiated by FDA? Yes
Telephone Number:
Communication Categorie(s):
Information Request
Author: HELEN GEMIGNANI
Telecon Summary:
TVC Numbers Information Request
FDA Participants:
Non-FDA Participants:
Trans-BLA Group: No
Related STNs: None
Related PMCs: None
Telecon Body:
From: Gemignani, Helen S
Sent: Tuesday, September 01, 2009 5:57 PM
To: Miller, Nancy; Lee, Martha (CBER)
Cc: Levis, Robin
Subject: Cervarix 09.01.2009 Telecon RE: TVC Numbers
Martha Lee, Nancy Miller and I called Matt Whitman, GSK, to inquire about two tables in the HPV-008 study report. Table 13 shows the number of recipients for TVC for HPV as 9319 and TVC for HAV as 9325. Supplement 192, of the same report, shows the number of recipients for TVC for HPV as 8667 and TVC for HAV as 8682. We asked GSK to resolve and provide CBER with an explanation for this discrepancy and for the correct values.
Mr. Whitman will get back to us.
Helen Sullivan Gemignani
Regulatory Project Manager
FDA/CBER/OVRR
Division of Vaccines and Related Products Applications/Viral Vaccine Branch
(301) 827-3070







